A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to compare the progression-free survival (PFS) in the 2
treatment arms
The secondary objectives of the study are :
- To compare the overall survival in the 2 treatment arms
- To compare the objective response rate in the 2 treatment arms
- To assess the safety profile of AVE8062 (in combination with the background cisplatin
therapy)
- To assess the pharmacokinetics of AVE8062 and its main metabolite, RPR258063, using a
population approach, in all patients enrolled in selected centers.